June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Clinical Outcome of Anti-VEGF in type 1 Choroidal Neovascularization secondary to Central Serous Chorioretinopathy
Author Affiliations & Notes
  • Jong Beom Park
    Kyung Hee Medical Center, Korea (the Republic of)
  • Kiyoung Kim
    Kyung Hee Medical Center, Korea (the Republic of)
  • Eung Suk Kim
    Kyung Hee Medical Center, Korea (the Republic of)
  • Seung-Young Yu
    Kyung Hee Medical Center, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Jong Beom Park, None; Kiyoung Kim, None; Eung Suk Kim, None; Seung-Young Yu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1914. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jong Beom Park, Kiyoung Kim, Eung Suk Kim, Seung-Young Yu; Clinical Outcome of Anti-VEGF in type 1 Choroidal Neovascularization secondary to Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1914.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the type 1 choroidal neovascularization (CNV) patients with central serous chorioretinopathy (CSC) patterns of fundus autofluorescence (FAF) abnormalities

Methods : This retrospective study included 19 eyes of 19 patients who were diagnosed with type 1 choroidal neovascularization with central serous chorioretinopathy (CSC) patterns of fundus autofluorescence abnormalities and characteristics of pachychoroid spectrum. Fundus autofluorescence patterns with spectral domain optical coherence tomography, best corrected visual acuity, subfoveal choroidal thickness and patterns of intravitreal anti-VEGF injection in type 1 choroidal neovascularization patients were analyzed.

Results : A total of 19 patients were consisted of 12 males and 7 females. The mean patients age was 68.79±7.55 years and the mean subfoveal choroidal thickness was 301.79±96.35 micron. Central serous chorioretinopathy (CSC) pattern of fundus autofluorescence abnormalities of type 1 choroidal neovascularization patients were grouped as mottled (36.8%), hyper (26.3%), hyper/hypo(36.8%). The mean number of intravitreal anti-VEGF injection per year was significantly lower in the hyper/hypo group than in the hyper group (p=0.046). Also there was a significant positive correlation between the subfoveal choroidal thickness and the interval of loading phase to maintenance phase of intravitreal anti-VEGF injection (r=0.458, p=0.049).

Conclusions : The central serous chorioretinopathy (CSC) patterns of fundus autofluorescence (FAF) abnormalities in type 1 choroidal neovascularization patients are helpful when predicting the number of intravitreal anti-VEGF injection per year. Additionally the interval of loading phase to maintenance phase of intravitreal anti-VEGF injection can be considering by the subfoveal choroidal thickness of type 1 choroidal neovascularization patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×